Know All About First FDA Approved Nasal Spray To Treat Severe Allergic Reactions
The FDA approved the first epinephrine nasal spray, Neffy, for the emergency…
Ascendis Pharma Lands Long-Awaited FDA Drug Approval in Rare Hormone Deficiency
Ascendis Pharma has received FDA approval for its hypoparathyroidism therapy, Yorvipath, providing…
New venture firm launches with $21M to invest in digital health
Create Health Ventures, a new VC firm, has launched with a $21…
Exercise Is Key for Parkinson’s Relief. But Bias, Underdiagnosis Hold Black Patients Back.
Organizers of a large exercise program for Parkinson's disease realized that most…
Heart attack, stroke incidence lower after COVID-19 vaccination
A study found that COVID-19 vaccination can lower the risk of heart…
STAT+: Pharmalittle: We’re reading about FDA rejecting MDMA; a nasal spray for allergic reactions, and more
The FDA rejected MDMA as a treatment for PTSD, despite positive Phase…
US approves first nasal spray for anaphylaxis
The FDA has approved Neffy, the first adrenaline nasal spray for treating…
Routine lab tests are not a reliable way to diagnose long COVID, finds study
A study supported by the NIH found that routine lab tests may…
Study reveals how light-activated macrophages increase their appetite for cancer cells
Researchers at UC Santa Barbara have discovered that using light to control…
FDA OKs New Drug for Treating Hypoparathyroidism
The FDA has approved a new drug called palopegteriparatide (Yorvipath) for the…